Malaria Vaccines Reach 25 African Countries in Record Rollout

Malaria still kills around 600,000 people every year, most of them children under five in sub-Saharan Africa, and for decades the disease resisted every attempt at a vaccine. That changed with two World Health Organization recommended vaccines, RTS,S and R21/Matrix-M, which are now being added to routine childhood immunisation schedules across the continent. By the middle of 2026, 25 African countries had introduced a malaria vaccine, and more than 58 million doses had been delivered through UNICEF and the global vaccine alliance Gavi. The R21 vaccine, developed at the University of Oxford and produced by the Serum Institute of India, showed about 75 percent efficacy in seasonal settings in its phase three trial, and a pricing deal agreed in late 2025 is set to cut its cost to under three dollars a dose. Health officials describe the rollout as one of the fastest in Gavi’s history, and the alliance aims to reach at least 50 million more children by 2030.
What the Evidence Shows
The scale of the campaign matters because malaria is not only a health crisis but an economic one, keeping children out of school and parents out of work across the region. The vaccines are given in a four-dose schedule to young children, starting at around five or six months of age, and they work best alongside bed nets, indoor spraying and prompt treatment. Early pilot programmes in Ghana, Kenya and Malawi recorded a drop of about 13 percent in all-cause mortality among eligible children and a fall of more than a fifth in hospital admissions for severe malaria. Challenges remain, including funding shortfalls, cold-chain logistics in remote districts and the need for parents to return for booster doses. Even so, researchers say the programme proves that a vaccine against a complex parasite can be delivered at national scale, and work continues on next-generation vaccines, including mRNA candidates that could offer longer-lasting protection. Reporting and analysis from sources such as National Science Foundation track the same developments, and specialists following malaria vaccine rollout in Africa say the direction is now consistent across independent lines of evidence.
The Wider Context
The wider context is a research landscape in which replication and open data now decide reputations. Findings connected to malaria vaccine rollout in Africa are being checked by independent groups with shared datasets, and the teams involved publish their methods in full so rivals can test every step. That discipline is slower than a headline cycle, but it is why results in this area increasingly survive first contact with scrutiny.
What Happens Next
What happens next in the story of malaria vaccine rollout in Africa will be decided by follow-up work already under way: larger samples, longer observation and instruments that have not yet come online. The researchers involved are unusually united on one point, that the current results justify the next investment of time and money. Readers will not have to wait long for the first tests of that claim. You can follow related developments in our coverage of science.
There is a practical lesson in all of this for readers deciding what to do today. Start with the verified facts, be wary of anyone promising certainty, and prefer reversible steps while the evidence is still developing. Circumstances differ by country, income and personal situation, so general guidance should always be weighed against your own context before you act on it in any significant or lasting way.



